ARTBIO
ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports.
ARTBIO
Industry:
Biotechnology Health Care Hospital Medical Medical Device Pharmaceutical
Founded:
2021-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.artbio.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
113 M USD
Technology used in webpage:
Amazon Equinix
Similar Organizations
Acorai
Acorai is a medical device manufacturer of non-invasive intracardiac pressure monitoring to improve heart failure management.
Asepha
AI clinical tools to enable automation and personalization in pharmacies.
EmployerDirect Healthcare
EmployerDirect Healthcare is a supplemental healthcare benefit that directs planned medical procedures to high-quality providers.
HCA
Hospital Corporation of America (HCA) provides healthcare services in locally managed facilities in 20 states in the U.S. and England.
HealNow
HealNow is the online payments and on-boarding platform for pharmacies.
Pomelo Care
Pomelo Care develops an online pregnancy care platform to provide virtual maternity and neonatal care services.
TriNetX
TriNetX is a health research network that connects drug discovery and development from pharmaceutical companies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Omega Funds
Omega Funds investment in Series A - ARTBIO
Third Rock Ventures
Third Rock Ventures investment in Series A - ARTBIO
F-Prime Capital
F-Prime Capital investment in Series A - ARTBIO
F-Prime Capital
F-Prime Capital investment in Seed Round - ARTBIO
Omega Funds
Omega Funds investment in Seed Round - ARTBIO
Key Employee Changes
| Date | New article |
|---|---|
| 2023-10-05 | ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific Officer |
Official Site Inspections
http://www.artbio.com Semrush global rank: 9.93 M Semrush visits lastest month: 288
- Host name: 147.75.40.150
- IP address: 147.75.40.150
- Location: Amsterdam Netherlands
- Latitude: 52.2832
- Longitude: 4.7521
- Timezone: Europe/Amsterdam
- Postal: 1119
More informations about "ARTBIO"
ARTBIO - Crunchbase Company Profile & Funding
ARTBIO may be growing as it has successfully raised significant capital and is actively collaborating with other companies to advance its radiopharmaceutical cancer therapies. The …See details»
ARTBIO Company Profile 2024: Valuation, Funding
ARTBIO General Information Description. Operator of a radiopharmaceutical company intended to offer a new approach to the treatment of cancer. The company specializes in radioligand therapy that delivers alpha or beta emitters …See details»
ARTBIO and Nucleus RadioPharma Announce Collaboration to …
May 7, 2024 CAMBRIDGE, Mass. and ROCHESTER, Minn. ─ May 7, 2024 ─ ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted …See details»
ARTBIO - LinkedIn
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a ...See details»
Artbio Company Profile - Office Locations, Competitors, Revenue …
Artbio has 5 employees across 4 locations and $90 m in total funding,. See insights on Artbio including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
ARTBIO - Funding, Financials, Valuation & Investors - Crunchbase
Jun 21, 2023 ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ... How much funding has this …See details»
Emanuele Ostuni – CEO, ARTBIO - pharmaboardroom.com
23 hours ago Emanuele Ostuni, CEO of ARTBIO, delves into the company’s innovative approach to radioligand therapies, focusing on its potential to replace chemotherapy and …See details»
ARTBIO
ARTBIO is redefining cancer care by developing a new class of alpha radioligand therapies (ART) and building the ecosystem that maximizes their potential. The ARTBIO Approach: Patients at …See details»
Nucleus RadioPharma unveils manufacturing pact with …
May 7, 2024 The production deal will support ARTBIO’s planned phase 1 and 2 clinical trials of its lead program in prostate cancer, AB001. ... manufacturing and supply chain organization for ...See details»
Behind the Breakthrough: Q&A with Emanuele Ostuni, …
Emanuele Ostuni is founding CEO of ARTBIO and worked closely with Roy Larsen and ARTBIO’s investors to build the company and its business model. Previously, he was head of Europe for Cell and Gene Therapies at Novartis …See details»
ARTBIO Launches to Develop New Class of Alpha Radioligand …
Jun 21, 2023 ARTBIO was founded in 2021 by Roy Larsen, Øyvind Bruland, Radforsk, and F-Prime Capital to create highly targeted cancer therapies by pairing the optimal alpha-emitting …See details»
Our Approach - ARTBIO
U.S. (Headquarters) ARTBIO Inc. c/o Alexandria LaunchLabs One Kendall Sq, B200, Suite 001 Cambridge, MA 02139 Switzerland ARTBIO GmbH Aeschengraben 9 4051 Basel, Switzerland …See details»
ARTBIO and Nucleus RadioPharma Announce Collaboration to …
May 7, 2024 ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), and NucleusSee details»
Investors pour $90M onto ARTBIO's palette 6 months after launch
Dec 7, 2023 ARTBIO launched less than six months ago with $23 million in seed funds, but in today’s dicey financing environment, there’s no better time than the present to corral new …See details»
ARTBIO Raises Oversubscribed and Upsized $90 Million Series A …
Dec 7, 2023 CAMBRIDGE, Mass., OSLO, Norway, LONDON, and BASEL, Switzerland, Dec. 7, 2023 /PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company …See details»
ARTBIO and Nucleus RadioPharma Announce Collaboration to …
May 7, 2024 CAMBRIDGE, Mass. and ROCHESTER, Minn., May 07, 2024--ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted …See details»
ARTBIO Raises Oversubscribed and Upsized $90 Million Series A …
Dec 7, 2023 ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), today announced the closing of an …See details»
AlphaGen Therapeutics and ARTBIO Announce Exclusive Strategic ...
About ARTBIO. ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach …See details»
FogPharma and ARTBIO Announce Collaboration to Co-Develop …
May 14, 2024 About ARTBIO ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The …See details»